UHR is an independent predictor of myocardial bridging and may serve as a useful biomarker for guiding clinical management, demonstrating the highest discriminative ability among inflammatory indices with an AUC of 0.853.
UHR, NLR, and MHR were all independent predictors of myocardial bridging in multivariate logistic regression analysis.
UHR demonstrated the highest discriminative ability for myocardial bridging among the inflammatory indices evaluated.
The study population was classified into two groups based on angiographic findings: patients with myocardial bridging (MB[+]) and a control group with normal coronary arteries.
Systemic metabolic and inflammatory markers were evaluated as potential indicators of myocardial bridging, a congenital coronary anomaly that may lead to adverse clinical outcomes.
This research examined whether a blood marker called the uric acid-to-HDL cholesterol ratio (UHR) is associated with a heart condition called myocardial bridging (MB), where a coronary artery runs through the heart muscle instead of along its surface. The study looked at 245 patients who had coronary angiography (an imaging test of the heart's arteries), finding that about half (52.6%) had myocardial bridging. The researchers calculated UHR along with two other inflammatory markers — the neutrophil-to-lymphocyte ratio (NLR) and the monocyte-to-HDL ratio (MHR) — to see which best identified patients with MB. The study found that all three markers were independently associated with the presence of myocardial bridging, but UHR performed best. With a cut-off value of 9.9, UHR correctly identified patients with myocardial bridging about 81% of the time (sensitivity) and correctly identified those without it about 80% of the time (specificity). The overall accuracy measure (AUC) was 0.853, indicating strong discriminative ability. This research suggests that UHR — a simple ratio derived from routine blood tests — could be a practical and inexpensive tool to help clinicians identify patients who may have myocardial bridging before or alongside coronary imaging. Since myocardial bridging is not always benign and can cause symptoms such as chest pain or arrhythmias, having an accessible screening marker could potentially improve clinical decision-making. However, as a retrospective cross-sectional study, it cannot establish causation, and further prospective studies would be needed to confirm these findings.
Hancıoğlu E, Özcan S, Bekler &, Enhoş A, Okuyan E. (2026). Association between serum uric acid-to-high-density lipoprotein cholesterol ratio and myocardial bridging: a cross-sectional study.. Cardiovascular journal of Africa. https://doi.org/10.5830/CVJA-2026-012